We have previously shown that low-dose fenofibrate treatment has an ability to prevent diabetes-induced nephropathy in rats. Diabetologia. However, until recently no reported study had been designed specifically to investigate the effects of intervening in patients with type 2 diabetes. The present study addresses the question of whether fenofibrate treatment in hypertriglyceridemic type 2 diabetic patients leads to changes in metabolic control, body mass index, leptin, free fatty acids, plasma insulin, and blood pressure. •• Chapman MJ, Ginsberg HN, Amarenco P et al. Treatment with low dose fenofibrate (30 mg/kg/day p.o.) normalizes the altered lipid profile in diabetic rats, whereas the low dose rosiglitazone (1mg/kg/day p.o.) treatment has no effect on lipid alteration in diabetic rats. The combination of fenofibrate and a statin is well tolerated, with no apparent increase in the risk of myopathy, unlike gemfibrozil-statin combination therapy.